Kestra Medical Technologies, Ltd. (KMTS)
As-reported financials and SEC filings for Kestra Medical Technologies, Ltd. The latest annual period is FY2026. The latest reported quarter is Q1 FY2027. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.
About Kestra Medical Technologies, Ltd.
Kestra Medical Technologies, Ltd. develops and commercializes wearable medical devices and digital healthcare solutions focused on cardiovascular disease. Its main product is the ASSURE wearable cardioverter defibrillator, a device designed to monitor and treat patients at risk of sudden cardiac arrest by delivering defibrillation shocks when needed. The company serves patients with elevated cardiac risk and healthcare providers by offering an integrated platform that includes monitoring, therapeutic treatment, and patient support services.
Snapshot
Fundamentals are from SEC filings for FY2026, the latest annual period (ended April 30, 2026). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
What changed at Kestra Medical Technologies
- Revenue grew 59.0% to $95M in FY2026, slower than the 115.1% the year before.
- Operating margin is -141.6% in FY2026, +164.2 pp against -305.8% in FY2024.
- Most recent quarter Q1 FY2027: revenue $31M, up 59.9% from Q1 FY2026.
- Free cash flow was negative $117M in FY2026.
- Net loss widened to $132M in FY2026, from $114M in FY2025.
Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.
Peer comparison
Where Kestra Medical Technologies’s fundamentals sit among the 88 medical device companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).
Kestra Medical Technologies’s revenue growth of +59.0% ranks in the 93rd percentile of the 87 medical device companies reporting it.
No reported insider purchases (code P) in the last 90 days; 31 insider sales totaling $6.0M. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →
Percentiles describe where a figure sits among industry peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.
Recent insider activity
Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.
| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
2026-09-30 filed 2026-10-01 | Raymond W. CohenDirector | Sell | 3.3K | $29.28 | $98K |
2026-09-21 filed 2026-09-23 | Elizabeth KwoDirector | Sell | 4.0K | $24.26 | $97K |
2026-09-08 filed 2026-09-10 | Conor HanleyDirector | Sell | 5.7K | $25.25 | $144K |
2026-09-08 filed 2026-09-10 | Mary Kay LadoneDirector | Sell | 3.9K | $25.20 | $98K |
2026-09-08 filed 2026-09-10 | Jeffrey Lawrence SchwartzDirector | Sell | 3.9K | $25.18 | $98K |
2026-09-08 filed 2026-09-10 | Kevin C. ReillyDirector | Sell | 2.9K | $25.13 | $74K |
2026-08-17 filed 2026-08-18 | Brian Daniel WebsterSee Remarks | Sell | 15.0K | $27.48 | $412K |
2026-08-07 filed 2026-08-11 | Vaseem MahboobChief Financial Officer | Sell | 25.8K | $25.87 | $667K |
2026-08-07 filed 2026-08-11 | Vaseem MahboobChief Financial Officer | Sell | 500 | $26.33 | $13K |
2026-08-04 filed 2026-08-06 | Brian Daniel WebsterSee Remarks | Sell | 48.6K | $24.47 | $1.2M |
2026-08-04 filed 2026-08-06 | Alfred J. Ford Jr.Chief Commercial Officer | Sell | 6.3K | $24.09 | $151K |
2026-08-04 filed 2026-08-06 | Vaseem MahboobChief Financial Officer | Sell | 3.9K | $25.17 | $99K |
Reported non-derivative purchases and sales (codes P/S), which may be open-market or private. Excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.
Short interest
Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 2026-09-30 | 3.3M | +4.9% | 7.28 |
| 2026-09-15 | 3.1M | +5.1% | 8.34 |
| 2026-08-31 | 3.0M | -1.5% | 12.36 |
| 2026-08-14 | 3.0M | -8.5% | 8.95 |
| 2026-07-31 | 3.3M | +6.4% | 10.19 |
| 2026-07-15 | 3.1M | -7.9% | 6.07 |
| 2026-06-30 | 3.4M | +14.7% | 7.35 |
| 2026-06-15 | 2.9M | +2.0% | 8.97 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.
Income statement (as reported)
| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | $95.1M | $59.8M | $27.8M |
| Gross profit | |||
| Operating income | $-134.7M | $-106.4M | $-85.1M |
| Net income | $-131.6M | $-113.8M | $-94.1M |
| Diluted EPS | $-2.43 | $-5.13 | $-5.07 |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.
Balance sheet (as reported)
| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Cash and equivalents | $99.7M | $237.6M | $8.2M |
| Current assets | $222.4M | $255.3M | $14.9M |
| Total assets | $358.5M | $295.7M | $45.9M |
| Current liabilities | $50.4M | $38.0M | $33.0M |
| Long-term debt | $42.6M | $41.1M | $42.5M |
| Total liabilities | $98.8M | $90.3M | $78.2M |
| Total equity | $259.7M | $205.4M | $-209.4M |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.
Cash flow (as reported)
| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Operating cash flow | $-81.7M | $-77.6M | $-72.2M |
| Capital expenditure | $34.9M | $22.9M | $12.2M |
| Free cash flow |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.
Quarterly trend
| Quarter | Revenue | Revenue YoY | Net income | Diluted EPS |
|---|---|---|---|---|
| Q1 FY2027 | $31.0M | 59.9% | $-44.1M | $-0.75 |
| Q4 FY2026 | 66.2% | |||
| Q3 FY2026 | $24.6M | 62.7% | $-34.2M | $-0.61 |
| Q2 FY2026 | $22.6M | 53.4% | $-32.8M | $-0.64 |
| Q1 FY2026 | $19.4M | 51.5% | $-25.8M | $-0.50 |
| Q4 FY2025 | — | |||
| Q3 FY2025 | $15.1M | — | $-21.5M | — |
| Q2 FY2025 | $14.7M | — | $-20.4M | — |
Latest 8 quarters, from company XBRL filings on SEC EDGAR. A dotted underline marks a fourth-quarter figure we calculated from the full year and the first nine months. Revenue YoY is our calculation too: each quarter against the same quarter a year earlier.
Company facts
Selected SEC filings
Largest medical device peers
Monitor KMTS
Get an alert when Kestra Medical Technologies files something material, see which superinvestors own it, and ask its filings a question with cited answers.
Monitor KMTS freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.